Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.62 |
| ▸ | MAOB | P27338 | 4/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | SDHA | P31040 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CALML3 | P27482 | 1/20 | 0.62 |
| ▸ | F10 | P00742 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1031592 | 1.00 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5917572 | 0.91 | MAOA (0.51) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13150910 | 0.90 | MAOA (0.50) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL12956323 | 0.89 | F10 (0.50) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL5911 | 0.89 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14026917 | 0.87 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3195071 | 0.87 | MAOA (0.58) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL14838111 | 0.86 | CALML3 (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL411137 | 0.86 | CALML3 (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13528070 | 0.86 | MAOA (0.60) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677679-A | Oxazolidinone compound containing biaryl hydrazone structure and preparation method and application thereof | 沈阳药科大学 | 2023-02-03 | — | — | CN | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9771345-B2 | Coferons and methods of making and using them | CORNELL UNIVERSITY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550783-B2 | Biaryl heterocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376400-B2 | Process for the synthesis of triazoles | MELINTA THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| US-7192974-B2 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2007-03-20 | — | — | US | disclosed |
| WO-2006133397-A2 | PROCESS FOR THE SYNTHESIS OF TRIAZOLES | RIB-X PHARMACEUTICALS, INC. (US) | 2006-12-14 | — | — | WO | disclosed |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | ASTRAZENECA AB (SE) | 2006-06-01 | — | — | US | disclosed |
| EP-1660465-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | Rib-X Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1599471-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | Astrazeneca AB (SE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2005012271-A2 | PROCESS FOR THE SYNTHESIS OF BIARYL OXAZOLIDINONES | RIB-X PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004078753-A1 | HYDROXYMETHYL SUBSTITUTED DIHYDROISOXAZOLE DERIVATIVES USEFUL AS ANTIBIOTIC AGENTS | ASTRAZENECA AB (SE) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116400-A1 | Oxazolidinone and/or isoxazoline derivatives as antibacterial agents | NR0B2, NR0B1, HRH2 | MAOA 293/4885MAOB 168/4885PTGS1 296/4885 |
| US-20060270637-A1 | Hydroxymethyl substituted dihydroisoxazole derivatives useful as antibiotic agents | RPS7, CYP3A7, CYP2A7 | MAOA 1154/4885MAOB 1493/4885PTGS1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.